Formulary E-news :
Having trouble viewing this e-mail? Click here.
You are subscribed to %%list.name%% as %%emailaddr%%.
Unsubscribe from this list.
Formulary E-news
Modern Medicine Network
 
 
 
 
 
TOP SEARCHES: Healthcare reform // Med safety // Gout
In this issue
ACEI, ARB risks
DNA testing
Ticagrelor use
Colorectal cancer
Antidepressants
Liraglutide and diabetes
Key Topic Updates

Survey

This month we would like to know...

How would you anticipate the passage of healthcare reform legislation will impact the activities/functions/role of the P&T Committee:

a) No Impact
   
b) Modest Impact
   
c) Significant Impact

Vote in our survey, and see what other P&T committee members have to say.
Click here to vote

Contact Us
Click here to contact a Formulary editor.

Click here to contact a Formulary sales representative.

Click here to learn about direct mail, reprints and classifieds in Formulary.

APRIL 9, 2010

Meeting Coverage

ACEI and ARB use in pregnancy an increasing concern
Despite being known teratogenic agents contraindicated in pregnancy, angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs) are being increasingly prescribed to women with hypertension during their childbearing years. This is leading to increased exposure to ACEIs and ARBs at the time of conception and during early pregnancy, and to an increased risk of serious birth defects and other adverse pregnancy outcomes, according to results of a study presented at the American College of Cardiology’s 59th annual scientific session. More...

Genetic testing may provide more accurate warfarin dose, lower risk of bleeding and clots
Physicians who check the DNA of patients before initiating warfarin therapy are more likely to provide the correct dose, avoiding the possibility of readmittance to a hospital, according to a new study presented in March at the American College of Cardiology’s 59th annual scientific session. More...

Use of ticagrelor leads to lower mortality after CABG surgery
Patients with acute coronary syndrome (ACS) who undergo coronary artery bypass graft (CABG) surgery are less likely to develop fatal outcomes when given ticagrelor instead of clopidogrel as an antiplatelet medication, according to research presented at the American College of Cardiology’s 59th annual scientific session in March. More...

Newer chemotherapies for metastatic colorectal cancer found to be more effective, but at significant cost
New chemotherapeutic agents for metastatic colorectal cancer offer improved survival time, however, at substantial cost, according to a recent economic analysis conducted by investigators at Emory University in Atlanta, and published online first (March 22 issue) in the Archives of Internal Medicine. More...
Healthcare professionals should contemplate antidepressants for patients with physical illnesses
Antidepressants can help depressed patients with physical illness, and healthcare professionals should consider them more often, according to researchers in London. More...
Liraglutide could improve glycemic control in patients with type 2 diabetes
A clinical study showed patients who switched from exenatide twice daily to liraglutide once daily experienced further reductions in hemoglobin A1c and weight loss when added to oral antidiabetes drugs (OADs). More...
Key Topic Updates
FDA Approvals
Tocilizumab (Actemra): An interleukin-6 receptor inhibitor for the treatment of rheumatoid arthritis
Liraglutide (Victoza): A GLP-1 analog approved for the treatment of type 2 diabetes
FDA actions in brief, March 2010 (Iprivask, VPRIV, Mirapex ER, Cayston, Menveo, Lamictal XR, Rituxan, Oleptro, Xiaflex, Norvir, Benicar, Crestor)
In the Pipeline
FDA Pipeline preview, March 2010 (CPI-300, Ondansetron, Intravenous acetaminophen, Gabapentin enacarbil, Rifaximin, ENMD-2076, Ap301, CM-AT, Fingolimod, Nilotinib)
Medication Safety
FDA imposes new safety requirements to curb use of LABAs in asthma patients
FDA finds no increased cardiovascular risk in patients using tiotropium

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your Inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.